The largest group of Black physicians, thought leaders, and celebrities were in one room to have a needed discussion about HIV.

The company had earlier said that its Q2 financial results were expected to take a $61 million hit due to acquired in-process ...

Gilead Sciences (($CC:GILD.CUR)) announced an update on their ongoing clinical study. Gilead Sciences is currently ...

Analysts expect Gilead Sciences to report an earnings per share (EPS) of $1.95. Investors in Gilead Sciences are eagerly ...

Now, let’s get to the juicy part. In a dataset that goes back to January 2019, the 4-6-U sequence has flashed 13 times on a ...

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be reporting results this Thursday after market close. Here’s ...

The stock's fall snapped a two-day winning streak.

Despite decades of medical progress, HIV continues to devastate Black communities. The statistics are sobering. The disparities, undeniable.

This was the stock's second consecutive day of gains.

On July 16, 49 attorneys general (AGs) announced that they joined a $202 million settlement with Gilead Sciences, Inc. (Gilead). Previously ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the top cheap pharmaceutical stocks to buy now. Morgan Stanley analyst Terence ...

CAMBRIDGE, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of ...